KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Enterprise Value (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Enterprise Value for 8 consecutive years, with -$167.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 15.95% year-over-year to -$167.9 million, compared with a TTM value of -$167.9 million through Dec 2025, down 15.95%, and an annual FY2025 reading of -$167.9 million, down 15.95% over the prior year.
  • Enterprise Value was -$167.9 million for Q4 2025 at Esperion Therapeutics, down from -$92.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$82.2 million in Q4 2023 and bottomed at -$259.3 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$161.2 million, with a median of -$164.6 million recorded in 2022.
  • The sharpest move saw Enterprise Value crashed 82.63% in 2022, then skyrocketed 54.54% in 2025.
  • Year by year, Enterprise Value stood at -$259.3 million in 2021, then skyrocketed by 35.66% to -$166.9 million in 2022, then soared by 50.71% to -$82.2 million in 2023, then tumbled by 76.01% to -$144.8 million in 2024, then dropped by 15.95% to -$167.9 million in 2025.
  • Business Quant data shows Enterprise Value for ESPR at -$167.9 million in Q4 2025, -$92.4 million in Q3 2025, and -$86.1 million in Q2 2025.